Answers are grounded in this paper and cite their sources.
Computational study demonstrates sub-millisecond screening of pathogenic PRNP variants with zero false positives, highlighting potential to expedite clinical trial eligibility in prion disease.
Human prion diseases, particularly Creutzfeldt-Jakob Disease (CJD), are characterized by rapid progression and a narrow therapeutic window. A documented mean diagnostic delay of 7.8 months - exceeding the median survival of 4 to 6 months - compromises patient eligibility for active clinical trials requiring early-stage disease. This paper describes the development of a computational proof-of-concept tool termed PRNP Variant Scanner, which applies the Rabin-Karp rolling hash algorithm and Paiva's Adaptive Window Heuristic to perform simultaneous multi-pattern screening of 16 pathogenic or clinically relevant variants of the human prion protein gene (PRNP). The approach detects variants in under 1 ms on sequences up to 759 bp, with a mathematically zero false-positive rate, and delivers integrated clinical interpretation including codon 129 haplotype status and eligibility information for the PRISM (NCT07444580) and PrProfile (NCT06153966) clinical trials.
No takes yet. Share an insight, caveat, or question.
Josenildo Paiva (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: